Browse News
Filter News
Found 513,045 articles
-
Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.
-
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
-
As investigations into China’s major vaccine scandals continue, a number of top regulators and politicians have been fired as a result. Bi Jingquan, former head of China’s Drug Administration, resigned. Two deputy Chinese provincial governors and one mayor were also fired by the Community Party o...
-
From Menopausal Nuns to Israeli Biotech: Israel’s BTG Developed First Genetically Modified Hormon...
8/16/2018
It’s been a while since FSH was manufactured using the urine of menopausal nuns. But now, an Israeli company, Bio-Technology General (BTG), owned by Italian company Ferring Pharmaceuticals, has developed a genetically-engineered version of FSH that can be personalized to improve the odds of a pat... -
Health Officials Remove Special NIH Oversite Rules Governing Gene Therapy Experiments: Report
8/16/2018
As gene therapies have become reality, the U.S. government is removing some special regulations that had been set up long ago over concerns of exotic safety risks. -
Regeneron and Teva’s Fasinumab Hits Primary and Secondary Endpoints in Late-Stage Sub Study
8/16/2018
Regeneron’s fasinumab hit the mark in a late-stage study assessing patients with chronic pain from osteoarthritis (OA) of the knee or hip. At 16 weeks patients experienced significantly less pain and also showed significantly improved functional ability from baseline. -
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
-
BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines
8/16/2018
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines. -
Buck Institute, Insilico Med and Juvenescence Found Napa Therapeutics to Focus on Age-Related Dis...
8/16/2018
Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longe... -
Shares of Sun Pharmaceuticals have climbed more than 3 percent this morning after the U.S. Food and Drug Administration approved its dry eye treatment Cequa (cyclosporine ophthalmic solution) 0.09 percent.
-
You Never Have a Second Chance to make a Good First Impression! When you are applying for a job online your resume is the first impression an organization will have of you.
-
Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma
8/16/2018
The IND approval will allow for the study of the Company's lead product candidate, STP705, in patients with advanced cholangiocarcinoma
-
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
8/16/2018
Data include final primary efficacy results and an interim safety analysis
-
Cambridge Analytica Whistleblower, Christopher Wylie, Keynotes Extraordinary Future Conference in Vancouver
8/16/2018
The Extraordinary Future Conference is returning to Vancouver on September 19-20 to showcase the hottest tech investment opportunities in Canada, many yet to hit the market.
-
FDA approves first generic version of EpiPen
8/16/2018
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds.
-
Microbial Activity in the Mouth May Differentiate Children with Autism Spectrum Disorder
8/16/2018
New research suggests that shifts in the bacteria within a child’s mouth could provide objective biomarkers for identifying autism spectrum disorder.
-
Back to School: It's Time to Update Your Child's Health Information
8/16/2018
Book bags are replacing beach totes as it quickly becomes time for students to go back to school. Organizing your child's health information, keeping current with doctor's appointments and planning for emergency scenarios should be part of every parent's seasonal routine, the nation's emergency doctors say.
-
New Research Reveals Dangers of Smoking Selfies on Social Media
8/16/2018
Big Tobacco gets a stream of free advertising from people on social media who post "smoking selfies," images that may help tobacco companies recruit more young smokers.
-
FallCall Solutions Partners with Mytrex, Inc. to Bring Personal Emergency Response Monitoring to Apple Watch® and iPhone®
8/16/2018
FallCall Solutions, the creator of the FallCall™ Lite app for Apple Watch and iPhone, has teamed up with Mytrex, Inc (d.b.a. Rescue Alert) to bring fully-integrated emergency medical monitoring services into the Apple Ecosystem.
-
Nurx Launches First-Ever End-to-End Telehealth HIV Prevention Service Line
8/16/2018
Nurx offers at-home lab testing to expand access to PrEP and combat escalating HIV rates